What We Do
Macrophage Repolarisation Technology
Immune System Re-programming For An Optimized Treatment Of Solid Tumor Types
Makrolife Biotech is an integrated pharmaceutical biotechnology company focused on developing Small Molecule therapies to control the immune system for immuno-oncology.
immunotherapy
tumor therapy by macrophage repolarization through small molecules
Small Molecules repolarize monocytes and macrophages into an inflammatory anti-tumoral M1 phenotype
An advanced therapeutic treatment
Makrolife Biotech is delevoping a groundbreaking application of macrophages, enhancing the traditional approach to immunotherapy by applying the benefits of macrophage genetics.
Makrolife Biotech is broadening the therapeutic potential of immunotherapy by targeting macrophages, the master regulator of the immune system. Macrophages can adopt several functional roles in response to signals from their environment.
Technology
Innovation
Platform
Makrolife Biotech´s unique therapeutic approach
Our macrophage repolarizing Small Molecules trigger natural biological switches that transform immuno-suppressive M2-like macrophages into pro-inflammatory, anti-tumorigenic macrophages.
These M1-like macrophages not only kill tumor cells, but also set in motion a cascade of signaling molecules that attract and turn on other cancer-fighting immune cells in the tumor microenvironment.
What We Do
